Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Obeticholic Acid 10 MG Clear all

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 33
States / cities: Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more

Conditions: Primary Biliary Cirrhosis
Interventions: Obeticholic Acid; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 4 more

Conditions: Primary Biliary Cholangitis
Interventions: Obeticholic Acid 5 MG, Obeticholic Acid 10 MG, Standard of Care: UDCA; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Non Alcoholic Steatohepatitis (NASH)
Interventions: Obeticholic Acid, Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 2,477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 175
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more

Conditions: Liver Cirrhosis, Biliary
Interventions: INT-747, Ursodeoxycholic Acid (URSO), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Alcoholic Hepatitis
Interventions: Placebo, 10 mg Obeticholic Acid (OCA); Drug
Lead sponsor: Naga P. Chalasani; Other
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Indianapolis, Indiana • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more

Conditions: Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions: Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 919 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 120
States / cities: Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more

Conditions: Healthy
Interventions: OCA 5 mg, OCA 10 mg, OCA 25 mg; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Alcohol Consumption
Interventions: Placebo, 10 mg Obeticholic Acid (OCA); Drug
Lead sponsor: Suthat Liangpunsakul; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Rialto, California • Sacramento, California • Miami, Florida + 8 more

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 43
States / cities: Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more

Conditions: Liver Cirrhosis, Biliary
Interventions: Placebo, Obeticholic Acid (OCA); Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 4
States / cities: Detroit, Michigan • Houston, Texas • Richmond, Virginia + 1 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: Obeticholic Acid, Atorvastatin, Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 22
States / cities: Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more

Conditions: Primary Biliary Cirrhosis
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 15
States / cities: Sacramento, California • San Diego, California • Aurora, Colorado + 11 more

Conditions: Healthy
Interventions: OCA 10 mg, OCA 25 mg; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hepatic Impairment
Interventions: obeticholic acid 10 mg; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Search by objective public record fields.

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)

Hepatic Impairment Trial of Obeticholic Acid